Fingolimod Real World Experience: Efficacy and Safety in Clinical Practice

Table 1

Weighted average of composed outcomes reported.

	WA	Max	Min	Nr	Pts
Patients	117	306	21	13	1515
Patients with NTZ as previous treatment	28,2%	100,0%	15,3%	7	741
Baseline ARR (previous 12 months)	0,64	1,20	0,34	6	606
Baseline MRI activity	78%	78%		1	100
Baseline EDSS	2,4	3,9	2,3	6	572
FU (months)	11,96	16,30	6,00	12	1494
Free of relapse and T1Gd+	93,5%	97,3%	89,1%	2	141
Free of EDDS progression and MRI activity	42%	42%	42%	1	37
Free of relapse and MRI activity	68,8%	87,6%	47,6%	3	504
Free of relapse and EDSS progression	66,6%	79,7%	56,3%	7	770
Free of relapse, EDDS progression, and MRI activity	62,5%	72,5%	50,3%	3	419

WA: weighted average; Max: maximum; Min: minimum; Nr: number of studies reported; Pts: number of patients.